Taysha Gene Therapies Issues Stock Grants to Four New Hires
Taysha granted RSUs and stock options to four new employees under its 2023 Inducement Plan, totaling over 476,000 shares.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) disclosed Thursday that its Board of Directors' Compensation Committee approved equity awards for four newly hired employees, effective October 1, 2026, as part of standard hiring incentives permitted under Nasdaq rules.
The grants consist of restricted stock units representing 384,000 shares of common stock and a stock option covering 92,400 shares. The awards were issued under the company's 2023 Inducement Plan, a vehicle specifically established to attract talent without requiring shareholder approval, as allowed by Nasdaq Listing Rule 5635(c)(4).
Read more Class Action Filed Against Fluence Energy Over Alleged Investor Harm →
Dallas-based Taysha focuses on developing adeno-associated virus gene therapies targeting severe monogenic diseases of the central nervous system. The inducement grant structure is a common mechanism among clinical-stage biotechnology firms competing for specialized scientific and operational personnel in a tight labor market.
Inducement plans under Nasdaq Rule 5635(c)(4) allow listed companies to grant equity to new employees as a material inducement to joining the firm, provided the awards are disclosed publicly. The rule is designed to give emerging-growth companies flexibility in recruiting without convening shareholder votes for each new hire grant.
Continue reading at GlobeNewswire - Industry News on Financial Services.
